Can omeprazole contribute to gout?

Can Omeprazole Contribute to Gout?

Based on the most recent and highest-quality evidence, omeprazole and other proton pump inhibitors (PPIs) are associated with an increased risk of developing gout, though the absolute risk appears modest and the mechanism is not fully established. 1

Evidence for PPI-Associated Gout Risk

The strongest recent evidence comes from a 2023 population-based case-control study from Taiwan involving millions of patients, which found that PPI use was positively associated with increased gout risk 1. Key findings include:

• Esomeprazole increased gout risk by 30% (adjusted OR 1.3; 95% CI 1.0-1.6)
• Risk was highest within the first 30 days of PPI treatment (adjusted OR 1.7; 95% CI 1.4-1.9), then attenuated over time
• Women had higher risk than men (adjusted OR 2.2; 95% CI 1.7-2.8)
• Middle-aged patients (41-60 years) had higher risk (adjusted OR 2.1; 95% CI 1.7-2.7) compared to older patients

However, an earlier 1997 UK cohort study of over 53,000 patients found no material association between omeprazole use and newly diagnosed gout when compared to H2-receptor blockers 2. This discrepancy may reflect differences in study design, population, or evolving understanding of PPI effects.

Important Nuance: Not All PPIs Carry Equal Risk

A 2025 retrospective cohort study from Taiwan provides critical guidance: lansoprazole appears to carry significantly lower gout risk compared to other PPIs 3. Among lansoprazole users, only 7.7% developed gout versus 13.3% in other PPI users, with an adjusted hazard ratio of 0.64 (95% CI 0.56-0.73). This suggests that if PPI therapy is necessary in patients at risk for gout, lansoprazole may be the preferred choice.

Clinical Context from Guidelines

While major gout guidelines 4, 5 do not specifically address omeprazole as a gout risk factor, they do emphasize that certain medications can contribute to hyperuricemia and gout. The 2017 EULAR guidelines specifically recommend: "When gout occurs in a patient receiving loop or thiazide diuretics, substitute the diuretic if possible" 5. This principle of medication review applies to PPIs as well.

Mechanism and FDA Safety Information

The FDA label for omeprazole does not list gout or hyperuricemia as recognized adverse effects 6. The proposed mechanism linking PPIs to gout involves increased insulin resistance, which can worsen hyperuricemia 3. Lansoprazole may counteract this by increasing expression of genes involved in adipogenesis.

Practical Clinical Approach

For patients requiring PPI therapy:

• If no gout history: Continue omeprazole with awareness of modest increased risk, particularly in the first month
• If gout risk factors present (male, middle-aged, hypertension, obesity): Consider switching to lansoprazole 3
• If active gout: Review necessity of PPI; if essential, prefer lansoprazole
• Monitor closely in first 30 days when risk is highest 1

For patients with new-onset gout on omeprazole:

• Do not automatically discontinue, as the association is modest
• Evaluate other stronger risk factors: diuretics, alcohol, diet, obesity 2
• Consider switching to lansoprazole if PPI therapy must continue 3

Common Pitfalls

• Overattributing gout to omeprazole: Traditional risk factors (age, male sex, BMI >30, hypertension, diuretics) are far stronger predictors 2
• Ignoring timing: Most drug-induced gout occurs within 30 days of initiation 1
• Not considering PPI alternatives: Lansoprazole offers a safer option for at-risk patients 3

The evidence suggests omeprazole can contribute to gout risk, but this should be weighed against its benefits and the availability of potentially safer alternatives like lansoprazole for high-risk patients.